iTeos Therapeutics (ITOS) said Thursday that it is deprioritizing inupadenant to "focus resources on other programs."
The company said it will present data from the dose escalation part of a a mid-stage trial evaluating inupadenant plus chemotherapy in non-small cell lung cancer at an event hosted by the European Society for Medical Oncology.
"While the initial signal for inupadenant's RP2D in the A2A-005 trial compared to chemotherapy alone is encouraging and supports its differentiated, insurmountable profile, we as well as our scientific and clinical advisory boards believe it does not meet sufficient level of clinical activity to warrant further investment," said iTeos chief executive officer Michel Detheux.
Detheux said the company will provide updates on its pipeline next year.
Shares of the company were up more than 2% in recent premarket activity.
Price: 8.50, Change: +0.20, Percent Change: +2.39
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。